<div><p>The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat model of Parkinson’s disease at 1-, 2-, 4-, 8-, 12-, and 16-months of age. The evaluation consisted of histopathology and ultrastructure examination of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematology, serum, and urine analysis. The LRRK2 knockout rat, starting at 2-months of age, displayed abnormal kidney staining patterns and/or morphologic changes that were associated with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat. Urinalysis indicated pronounced changes in LRRK2 knockout rats in uri...
Mutations in leucine-rich repeat kinase 2 (LRRK2) segregate with familial Parkinson’s disease (PD) a...
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, i...
Background: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinso...
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat mode...
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat mode...
<div><p>Genetic evidence links mutations in the LRRK2 gene with an increased risk of Parkinson’s dis...
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the...
Abstract Background Dominantly inherited missense mutations in leucine-rich repeat kinase 2 (LRRK2) ...
Mutations in the LRRK2 gene are the most common cause of genetic Parkinson’s disease. Although the m...
Mutations in the LRRK2 gene are the most common cause of genetic Parkinson's disease. Although the m...
Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene on chromosome 12 cause autosomal dominant...
The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial P...
Mutations and variations in the leucine-rich repeat kinase 2 (LRRK2) gene are strongly associated wi...
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions of people gl...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson&apo...
Mutations in leucine-rich repeat kinase 2 (LRRK2) segregate with familial Parkinson’s disease (PD) a...
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, i...
Background: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinso...
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat mode...
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat mode...
<div><p>Genetic evidence links mutations in the LRRK2 gene with an increased risk of Parkinson’s dis...
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the...
Abstract Background Dominantly inherited missense mutations in leucine-rich repeat kinase 2 (LRRK2) ...
Mutations in the LRRK2 gene are the most common cause of genetic Parkinson’s disease. Although the m...
Mutations in the LRRK2 gene are the most common cause of genetic Parkinson's disease. Although the m...
Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene on chromosome 12 cause autosomal dominant...
The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial P...
Mutations and variations in the leucine-rich repeat kinase 2 (LRRK2) gene are strongly associated wi...
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions of people gl...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson&apo...
Mutations in leucine-rich repeat kinase 2 (LRRK2) segregate with familial Parkinson’s disease (PD) a...
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, i...
Background: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinso...